Mankind Pharma's credit ratings reaffirmed by CRISIL, including Rs 2,500 crore in debentures

Mankind Pharma Ltd announced today, October 29, 2026, that CRISIL Ratings Limited (“CRISIL”) has reaffirmed and withdrawn credit ratings for several of the company’s instruments, as per Regulation 30 & 51 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Specifically, CRISIL reaffirmed the rating of “Crisil AA+/Stable” for Non-Convertible Debentures amounting to Rs 400 crore and another tranche of Non-Convertible Debentures amounting to Rs 2,100 crore, while withdrawing the “Crisil AA+/Stable” rating previously assigned to Non-Convertible Debentures totaling Rs 2,500 crore; additionally, CRISIL has withdrawn the “Crisil A1+” rating for Commercial Paper valued at Rs 1,500 crore, with the detailed rationale accessible via a link provided in the release and also on the company’s website at www.mankindpharma.com.